Stock A206650 EUBIOLOGICS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

EuBiologics Co., Ltd. Stock

Equities

A206650

KR7206650004

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
13,830 KRW +2.90% Intraday chart for EuBiologics Co., Ltd. +10.20% +20.58%
Jan. 29 Zimbabwe launches door-to-door cholera vaccination campaign RE
2023 Pop Biotechnologies and Eubiologics' Eucorvac-19 Vaccine Hits Target in Phase 3 Trial CI

Financials

Sales 2024 * 116B 84.45M Sales 2025 * 128B 93.18M Capitalization 490B 357M
Net income 2024 * 29B 21.11M Net income 2025 * 34B 24.75M EV / Sales 2024 * 4.34 x
Net Debt 2024 * 14B 10.19M Net Debt 2025 * 14B 10.19M EV / Sales 2025 * 3.94 x
P/E ratio 2024 *
16.6 x
P/E ratio 2025 *
14.5 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 80.12%
More Fundamentals * Assessed data

Chart EuBiologics Co., Ltd.

Dynamic Chart

Latest news about EuBiologics Co., Ltd.

Zimbabwe launches door-to-door cholera vaccination campaign RE
Pop Biotechnologies and Eubiologics' Eucorvac-19 Vaccine Hits Target in Phase 3 Trial CI
EuBiologics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Eubiologics Co., Ltd. Announces Phase Iii Clinical Trial Ind Approval of Eucorvac-19, Covid-19 Vaccine Candidate, in South Korea CI
Clips Co., Ltd. announced that it expects to receive KRW 2.50003 billion in funding from EuBiologics Co., Ltd., SK bioscience Co.,Ltd., BNC Korea Co., Ltd. CI
SK bioscience : S.Korea to begin producing Novavax COVID-19 vaccine as early as June RE
EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in Korea CI
EuBiologics Co., Ltd.(KOSDAQ:A206650) added to S&P Global BMI Index CI
ATGC Co., Ltd. announced that it has received KRW 2.1 billion in funding from EuBiologics Co., Ltd. CI
ATGC Co., Ltd. announced that it expects to receive KRW 2.1 billion in funding from EuBiologics Co., Ltd. CI
EuBiologics Co., Ltd. announced that it has received KRW 30.00000351 billion in funding CI
EuBiologics Co., Ltd. announced that it expects to receive KRW 30 billion in funding CI
Global Health Investment Fund I, LLC, managed by Global Health Investment Advisors, LLC acquired 6.19% stake in EuBiologics Co., Ltd.. CI
EuBiologics Co., Ltd. has completed an IPO in the amount of KRW 19.2 billion. CI
EuBiologics Co., Ltd. has filed an IPO. CI
More news

Press releases EuBiologics Co., Ltd.

Gavi and UNICEF welcome approval of new oral cholera vaccine AQ
Gavi and Unicef Welcome Approval of New Oral Cholera Vaccine [press release] AQ
What's Behind the Worldwide Shortage of Cholera Vaccines? for Starters, They're Only Made By One Company [analysis] AQ
Gavi - Global vaccine alliance outlines path to sustainable cholera vaccine supply AQ
POP Biotechnologies' SNAP Vaccine System Safe and Effective in a Phase II Clinical Trial for COVID-19 AQ
More press releases

News in other languages on EuBiologics Co., Ltd.

Reservas de vacunas contra el cólera, "vacías" ante aumento de casos
More news

Quotes and Performance

1 day-1.18%
1 week+7.09%
Current month+10.89%
1 month+5.25%
3 months+31.76%
6 months+34.40%
Current year+17.18%
More quotes

Highs and lows

1 week
12 160.00
Extreme 12160
14 500.00
1 month
11 490.00
Extreme 11490
14 500.00
Current year
10 060.00
Extreme 10060
14 500.00
1 year
6 260.00
Extreme 6260
14 500.00
3 years
6 260.00
Extreme 6260
61 500.00
5 years
4 655.00
Extreme 4655
61 500.00
10 years
3 650.00
Extreme 3650
61 500.00
More quotes

Managers and Directors - EuBiologics Co., Ltd.

Managers TitleAgeSince
Yeong-Ok Baek CEO
 Chief Executive Officer 61 04-12-31
Suk-Keun Choi DFI
 Director of Finance/CFO 57 10-07-31
Kyeong-Ho Min BRD
 Director/Board Member 55 10-11-30
Members of the board TitleAgeSince
Suk-Keun Choi DFI
 Director of Finance/CFO 57 10-07-31
Yeong-Ok Baek CEO
 Chief Executive Officer 61 04-12-31
Kyeong-Ho Min BRD
 Director/Board Member 55 10-11-30
More insiders

Quotes

Date Price Change Volume
24-04-24 13,830 +2.90% 675 371
24-04-24 13,440 -1.18% 538,128
24-04-23 13,600 +0.37% 753,981
24-04-22 13,550 +6.61% 5,191,208
24-04-19 12,710 +0.39% 453,331

End-of-day quote Korea S.E., April 23, 2024

More quotes

Company Profile

EuBiologics Co Ltd is a Korea-based company mainly engaged in the manufacture and sale of biopharmaceuticals. The Company operates its business through two segments. The Vaccine segment manufactures and sells oral cholera vaccines. The Contract Research and Manufacturing Organization (CRMO) segment contracts, researches and manufactures biopharmaceuticals.
Sector
Pharmaceuticals
Calendar
2024-05-09 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
EUBIOLOGICS CO., LTD. Stock EuBiologics Co., Ltd.
+17.18% 356M
CSL LIMITED Stock CSL Limited
-2.86% 87.31B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+3.95% 40.86B
BIOGEN INC. Stock Biogen Inc.
-21.94% 29.36B
UCB Stock UCB
+56.65% 24.49B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-5.41% 17.31B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-44.23% 11.26B
INCYTE CORPORATION Stock Incyte Corporation
-17.60% 11.62B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-13.96% 11.31B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+6.37% 8.31B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. A206650 Stock